# How Antibodies Can Force Cancer Cells to Self-Destruct

> Genentech's patent on specific antibodies that bind to the Apo-2 receptor to trigger programmed cell death in cancer cells.

- **Patent:** US 7807153
- **Original title:** Apo-2 receptor agonist antibodies
- **Owner:** Genentech Inc
- **Granted:** 2010
- **Status:** Public domain (expired)
- **Times cited:** 2
- **Field:** biotech, pharmaceutical

## What it does

This patent describes monoclonal antibodies designed to target and bind to a specific protein called Apo-2, which is found on the surface of certain cells. When these antibodies attach to the Apo-2 receptor, they act as agonists, meaning they trigger a signal inside the cell that forces it to undergo apoptosis, or programmed cell death. By specifically targeting cancer cells that express this receptor, the antibodies can cause the tumor cells to kill themselves without necessarily harming healthy cells. For example, the patent demonstrates this effect in SK-MES-1 lung carcinoma cells.

## What it does NOT cover

- Does not cover antibodies that bind to receptors other than Apo-2.
- Does not cover antibodies that block or inhibit apoptosis rather than triggering it.
- Does not cover small molecule drugs or chemical compounds that are not antibodies.
- Does not cover general methods of cancer treatment that do not use these specific agonist antibodies.

## The clever bit

The innovation lies in using an antibody not just to block a signal, but to actively mimic a natural trigger that forces the cell to initiate its own suicide sequence (apoptosis).

## Real-world examples

1. Targeted cancer immunotherapy research
2. Experimental monoclonal antibody therapeutics
3. Oncology drug development pipelines

## Why it matters

This patent represents a significant effort in targeted cancer therapy, moving away from broad-spectrum chemotherapy toward precision medicine. By leveraging the body's own cell-death pathways, Genentech aimed to create treatments that are more selective and potentially less toxic to patients. It highlights the importance of identifying specific cell-surface receptors that can be exploited to force malignant cells into self-destruction.

## Frequently asked questions

### What does How Antibodies Can Force Cancer Cells to Self-Destruct cover?

Genentech's patent on specific antibodies that bind to the Apo-2 receptor to trigger programmed cell death in cancer cells.

### Who owns patent US 7807153?

Genentech Inc owns this patent, granted in 2010.

### When does this patent expire?

This patent is expected to expire on October 5, 2030, when the invention enters the public domain.

### What is patent US 7807153 cited by?

This patent has been cited by 2 later patents that build on its ideas.

### What problem does this patent solve?

This patent represents a significant effort in targeted cancer therapy, moving away from broad-spectrum chemotherapy toward precision medicine. By leveraging the body's own cell-death pathways, Genentech aimed to create treatments that are more selective and potentially less toxic to patients. It highlights the importance of identifying specific cell-surface receptors that can be exploited to force malignant cells into self-destruction.

### What does this patent NOT cover?

Does not cover antibodies that bind to receptors other than Apo-2.

**Full plain-English explainer:** https://patentbrief.org/patent/us/7807153/avastin-chemotherapy

**Original patent:** https://patents.google.com/patent/US7807153

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._